Intellia Posts 3-Year Data Showing Lonvo-z Cuts HAE Attacks By 98% After One Dose

Intellia Therapeutics' lonvo-z (NTLA-2002), a CRISPR/Cas9-based therapy for hereditary angioedema (HAE), demonstrated a 98% average reduction in monthly HAE attack rates in Phase 1/2 study patients after three years, with a median of 23 months attack- and treatment-free. The Phase 3 HAELO trial has completed patient screening ahead of schedule with top-line data expected in the first half of 2026, and a BLA submission planned for 2026 with a potential U.S. launch in 2027. Following the announcement, NTLA shares are up 5.48%.

Analysis

Intellia Therapeutics (NTLA) has presented highly encouraging three-year follow-up data from its Phase 1/2 study of lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) for hereditary angioedema (HAE). A single dose of the CRISPR/Cas9-based therapy resulted in a 98% average reduction in monthly HAE attack rates and a median of 23 months attack- and treatment-free across all 10 patients, underscoring its potential for profound and durable efficacy. The therapy demonstrated dose-dependent reductions in plasma kallikrein and was well-tolerated, with only mild, transient infusion-related reactions and no serious treatment-related adverse events observed, even in long-term follow-up. This strong safety and efficacy profile has supported the acceleration of the global Phase 3 HAELO trial, which has now completed patient screening ahead of schedule. Intellia anticipates top-line data from this pivotal trial in the first half of 2026, with a Biologics License Application (BLA) submission planned for 2026 and a potential U.S. launch in 2027. Lonvo-z's development as a one-time intravenous gene editing treatment targeting the KLKB1 gene, coupled with multiple supportive global regulatory designations including FDA Orphan Drug and RMAT, EMA PRIME, and UK MHRA Innovation Passport, positions it as a potentially transformative therapy in HAE. The positive news has been reflected in Intellia's stock, which is trading up 5.48%.

Key Decisions for Investors

• Investors should recognize the significant clinical validation and potential market disruption lonvo-z represents, given the robust long-term efficacy, favorable safety profile, and one-time treatment paradigm for HAE.
• Closely monitor upcoming catalysts, particularly the HAELO Phase 3 trial top-line data release in H1 2026 and subsequent BLA submission, as these events will be critical for further de-risking and value realization.
• While the current data and regulatory progress are highly positive, maintain awareness of the inherent risks associated with late-stage clinical development and the competitive landscape for HAE treatments, factoring these into position sizing and risk management.